TY - JOUR
T1 - Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline
AU - Debette, S.
AU - Seshadri, S.
AU - Beiser, A.
AU - Au, R.
AU - Himali, J. J.
AU - Palumbo, C.
AU - Wolf, P. A.
AU - DeCarli, C.
N1 - Funding Information:
Study funding: This work (design and conduct of the study, collection and management of the data) was supported by the Framingham Heart Study's National Heart, Lung, and Blood Institute contract ( N01-HC-25195 ) and by grants from the National Institute of Neurological Disorders and Stroke ( R01 NS17950 ) and from the National Institute on Aging ( R01 AG16495; AG08122; AG033193; AG031287 ). Dr. Debette was supported by a Fulbright grant and received an award from the Bettencourt-Schueller Foundation.
Funding Information:
Dr. Debette reports no disclosures. Dr. Seshadri serves as an Associate Editor for the Journal of Alzheimer's Disease and on the editorial board of Stroke and receives research support from the NIH (NIA, NINDS, NHLBI). Dr. Beiser receives publishing royalties for Introductory Applied Statistics (Brooks Cole, 2005) and receives research support from the NIH (NIA, NINDS, NHLBI). Dr. Au receives/has received research support from the NIH (NIA, NINDS) and the Wing Tat Lee Fund. J.J. Himali reports no disclosures. Dr. Palumbo serves as a consultant for the NIH/NIDCD; receives salary support from the NIH/NIA; and receives research support from the VA Boston Healthcare System R&D Service (via an IPA to Boston University School of Medicine) to chair the Institutional Review Board. Dr. Wolf receives publishing royalties from the 5th edition of Stroke: Pathophysiology, Diagnosis, and Management (Elsevier, 2008) and receives research support from the NIH (NHLBI, NINDS, NIA). Dr. DeCarli serves as Editor-in-Chief of Alzheimer Disease and Associated Disorders; serves as a consultant for Takeda Pharmaceutical Company Limited and Avanir Pharmaceuticals; and receives research support from Merck Serono and the NIH (NIA, NHLBI).
PY - 2011/8/2
Y1 - 2011/8/2
N2 - Objective: Our aim was to test the association of vascular risk factor exposure in midlife with progression of MRI markers of brain aging and measures of cognitive decline. Methods: A total of 1,352 participants without dementia from the prospective Framingham Offspring Cohort Study were examined. Multivariable linear and logistic regressions were implemented to study the association of midlife vascular risk factor exposure with longitudinal change in white matter hyperintensity volume (WMHV), total brain volume (TBV), temporal horn volume, logical memory delayed recall, visual reproductions delayed-recall (VR-d), and Trail-Making Test B-A (TrB-A) performance a decade later. Results: Hypertension in midlife was associated with accelerated WMHV progression (p < 0.001) and worsening executive function (TrB-A score; p = 0.012). Midlife diabetes and smoking were associated with a more rapid increase in temporal horn volume, a surrogate marker of accelerated hippocampal atrophy (p = 0.017 and p = 0.008, respectively). Midlife smoking also predicted a more marked decrease in total brain volume (p = 0.025) and increased risk of extensive change in WMHV (odds ratio = 1.58 [95% confidence interval 1.07-2.33], p = 0.021). Obesity in midlife was associated with an increased risk of being in the top quartile of change in executive function (1.39 [1.02-1.88], p = 0.035) and increasing waist-to-hip ratio was associated with marked decline in TBV (10.81 [1.44-81.01], p = 0.021). Longitudinal changes in brain structure were significantly correlated with decline in memory and executive function. Conclusions: Midlife hypertension, diabetes, smoking, and obesity were associated with an increased rate of progression of vascular brain injury, global and hippocampal atrophy, and decline in executive function a decade later.
AB - Objective: Our aim was to test the association of vascular risk factor exposure in midlife with progression of MRI markers of brain aging and measures of cognitive decline. Methods: A total of 1,352 participants without dementia from the prospective Framingham Offspring Cohort Study were examined. Multivariable linear and logistic regressions were implemented to study the association of midlife vascular risk factor exposure with longitudinal change in white matter hyperintensity volume (WMHV), total brain volume (TBV), temporal horn volume, logical memory delayed recall, visual reproductions delayed-recall (VR-d), and Trail-Making Test B-A (TrB-A) performance a decade later. Results: Hypertension in midlife was associated with accelerated WMHV progression (p < 0.001) and worsening executive function (TrB-A score; p = 0.012). Midlife diabetes and smoking were associated with a more rapid increase in temporal horn volume, a surrogate marker of accelerated hippocampal atrophy (p = 0.017 and p = 0.008, respectively). Midlife smoking also predicted a more marked decrease in total brain volume (p = 0.025) and increased risk of extensive change in WMHV (odds ratio = 1.58 [95% confidence interval 1.07-2.33], p = 0.021). Obesity in midlife was associated with an increased risk of being in the top quartile of change in executive function (1.39 [1.02-1.88], p = 0.035) and increasing waist-to-hip ratio was associated with marked decline in TBV (10.81 [1.44-81.01], p = 0.021). Longitudinal changes in brain structure were significantly correlated with decline in memory and executive function. Conclusions: Midlife hypertension, diabetes, smoking, and obesity were associated with an increased rate of progression of vascular brain injury, global and hippocampal atrophy, and decline in executive function a decade later.
UR - http://www.scopus.com/inward/record.url?scp=80051508807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051508807&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318227b227
DO - 10.1212/WNL.0b013e318227b227
M3 - Article
C2 - 21810696
AN - SCOPUS:80051508807
SN - 0028-3878
VL - 77
SP - 461
EP - 468
JO - Neurology
JF - Neurology
IS - 5
ER -